1 |
Johnston JN, Kadriu B, Allen J, Gilbert JR, Henter ID, Zarate CA Jr. Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology 2023;226:109422. [PMID: 36646310 DOI: 10.1016/j.neuropharm.2023.109422] [Reference Citation Analysis]
|
2 |
Peterson A, Largent EA, Lynch HF, Karlawish J, Sisti D. Journeying to Ixtlan: Ethics of Psychedelic Medicine and Research for Alzheimer’s Disease and Related Dementias. AJOB Neuroscience 2022. [DOI: 10.1080/21507740.2022.2148771] [Reference Citation Analysis]
|
3 |
Kelly DF, Heinzerling K, Sharma A, Gowrinathan S, Sergi K, Mallari RJ. Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology. Neurosurgery 2022;Publish Ahead of Print. [DOI: 10.1227/neu.0000000000002275] [Reference Citation Analysis]
|
4 |
López-arnau R, Camarasa J, Carbó M, Nadal-gratacós N, Puigseslloses P, Espinosa-velasco M, Urquizu E, Escubedo E, Pubill D. 3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs. Front Psychiatry 2022;13:990405. [DOI: 10.3389/fpsyt.2022.990405] [Reference Citation Analysis]
|
5 |
Nichols CD, Nichols DE. Preface to the special issue "Psychedelics and Neurochemistry". J Neurochem 2022. [PMID: 35699130 DOI: 10.1111/jnc.15651] [Reference Citation Analysis]
|
6 |
Schirò G, Balistreri CR. The close link between brain vascular pathological conditions and neurodegenerative diseases: Focus on some examples and potential treatments. Vascul Pharmacol 2021;142:106951. [PMID: 34942382 DOI: 10.1016/j.vph.2021.106951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|